Leukemia, Lymphoma, Myeloma Cancer News |Hematologic & Blood

Hematologic Cancers News

HEMATOLOGIC CANCER ADVISOR

Hematologic Cancers News

Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication

The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Next post in Chronic Lymphocytic Leukemia